Shionogi & Co Ltd

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.; hereafter “Maze”) announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 (GYS1) inhibitor that.

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q2 2023 Earnings Conference Call October 31, 2023 9:30 PM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Isao Teshirogi - Representative Director, President and CEO Toshinobu Iwasaki - Senior Executive Officer, SVP, Healthcare Business Supervisory Unit and Pharmaceutical Commercial Division Koji Hanasaki - Senior Executive Officer, SVP, Supply Supervisory Unit and Global Business Division Conference Call Participants Eiji Ueda - Goldman Sachs Kazuaki Hashiguchi - Daiwa Hiroyuki Matsubara - Nomura Securities Hiroshi Wada - SMBC Hidemaru Yamaguchi - Citi Seiji Wakao - JPMorgan Yoshimasa Kyokawa Ladies and Gentlemen, time has come to start the meeting.

Shionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call July 31, 2023 5:15 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications John Keller - Senior Executive Officer, SVP, R&D Supervisory Unit Toshinobu Iwasaki - Senior Executive Officer, SVP, Healthcare Business Supervisory Unit and Pharmaceutical Commercial Division Koji Hanasaki - Executive Officer, SVP, Supply Supervisory Unit and Global Business Division Noriyuki Kishida - Senior Executive Officer, SVP, Corporate Supervisory Unit Ryuichi Kiyama - Senior Executive Officer, SVP, Corporate Strategy Division Takeki Uehara - Corporate Officer, SVP, Drug Development and Regulatory Science Division Masako Kudou - VP, Finance & Accounting Department Conference Call Participants Eiji Ueda - Goldman Sachs Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit Suisse Seiji Wakao - JPMorgan Securities Stephen Barker - Jeffries Securities Shinya Tsuzuki - Mizuho Securities Luca Sogi - Sanford Bernstein Yoshimasa Kyokawa [Foreign Language] [Interpreted] I'm Kyokawa of Shionogi [IR] Department and thank you very much for your participation out of your very busy schedule.

Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript

Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside.

Shionogi: Likely The Last Viable COVID Play

Shionogi & Co., Ltd. (OTCPK:SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and Accounting Department Ryuichi Kiyama - Senior Executive Officer and Senior Vice President, Corporate Strategy Division and Corporate Planning Department Takeki Uehara - Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division Toshinobu Iwasaki - Senior Executive Officer, Senior Vice President, Healthcare Business Supervisory Unit and Pharmaceutical Conference Call Participants Motoya Kohtani - Nomura Securities Eiji Ueda - Goldman Sachs Hidemaru Yamaguchi - Citi Fumiyoshi Sakai - Credit Suisse Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Kazuaki Hashiguchi - Daiwa Securities Yoshimasa Kyokawa Hello, everyone.

Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript

News for Shionogi & Co Ltd Stock (SGIOY)